Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
|Articles|November 1, 2000
Oncology NEWS International
- Oncology NEWS International Vol 9 No 11
- Volume 9
- Issue 11
Grants to Conquer the ‘Digital Divide’
BETHESDA, Md-The National Cancer Institute has given four awards totaling $932,000 to four existing NCI contractors to develop research to understand, and pilot programs to breach, the “Digital Divide” that prevents many members of minorities from accessing cancer information on the Internet.
Advertisement
BETHESDA, MdThe National Cancer Institute has given four awards totaling $932,000 to four existing NCI contractors to develop research to understand, and pilot programs to breach, the Digital Divide that prevents many members of minorities from accessing cancer information on the Internet.
The four awards went to contractors who operate regional information centers for NCIs Cancer Information Service (CIS). They will cover 1 year, with the possibility of a 6-month extension.
The awardees are the CIS New York State (Memorial Sloan-Kettering Cancer Center); CIS North Central and Mid-West Regions (University of Wisconsin, Madison, and Karmanos Cancer Center, Detroit); CIS New England Region (Yale Cancer Center); and CIS Mid-South Region (Markey Cancer Cener, Kentucky, and the Louisiana State University Health Sciences Center).
Articles in this issue
about 26 years ago
Joe & Ali Torre Lead ‘Two Against One’ Prostate Cancer Campaignabout 26 years ago
Efforts to Reduce Tobacco Deaths May Fail in the Short Termabout 26 years ago
Data Published for First-Line Irinotecanabout 26 years ago
Manufacturing Capability a Factor in Success of New Biologicsabout 26 years ago
Report Finds States Not Using Tobacco Funds for Preventionabout 26 years ago
NCI Intramural Program Challenged to ‘Reinvent Itself’about 26 years ago
Surgery Supported for Recurring Colorectal Cancerabout 26 years ago
Breast Cancer Stamp Funds $6.7 Million in 2-Year NCI Grantsabout 26 years ago
Human Side of Cancer Offers Insights on Coping With the DiseaseAdvertisement
Related to this article
Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative PD-L1 gastroesophageal cancer.
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
4
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
5